On September 16, 2021, leading experts from the SITC Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel presented the "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immune Checkpoint Inhibitor-related Adverse Events." This high-level webinar covered advanced concepts of toxicity management and risk factors drawing from recommendations within the Clinical Practice Guideline (CPG). The recorded webinar and presentation slides are available below.
The webinar discussed management of toxicities associated with immune checkpoint inhibitor (ICI) therapies and their risk factors, including:
Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org, or check out our free CPG mobile app.
This webinar is supported, in part, by independent medical education grant funding from Amgen and Merck & Co., Inc.The SITC Clinical Practice Guidelines are produced by SITC and have no funding from outside sources.#Adverse Events #Presentation Slides #Recorded Webinar #Clinical Practice Guideline #Clinician#Nurse Practitioner #Pharmacist #Primary Care Physician #Registered Nurse #2021
Meeting: SITC CPG Webinar – Practical Management Pearls for Immune Checkpoint Inhibitor-related Adverse Events; Faculty: Julie R. Brahmer, MD, MSc – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Marc S. Ernstoff, MD – National Institutes of Health; David E. Gerber, MD — Harold C. Simmons Comprehensive Cancer Center, UT Southwestern; Jarushka Naidoo, MBBCH, MHS – Beaumont RCSI Cancer Centre Dublin; Jeffrey A. Sosman, MD – Northwestern University; Date: September 16, 202100:57:29
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org